Navigation Links
The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: Melanocortin • receptor binding assay • LEADseeker • SPA Imaging Beads


Pro-melanocortins are present in high levels in the pituitary and are processed into three major peptide hormone fragments: adrenocorticotrophin (ACTH), the melanocyte stimulating hormones, and β-endorphin. The various melanocyte stimulating hormones are known to activate the MC5 (melanocortin subtype 5) receptor. The melanocortin 5 receptor (MC5R) in particular is expressed in numerous human peripheral tissues including adrenal gland, leukocytes, and many others. The only firmly established function of MC5R is its participation in exocrine function particularly sebaceous gland secretion. The role of MC5R in exocrine secretion has the potential to be exploited for the treatment of skin disorders such as acne and dermatitis (1).

This application note describes a 384-well melanocortin MC5 receptor binding assay, which has been developed on the LEADseeker™ Multimodality Imaging System.


Materials
Products used

LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) PEI RPNQ0289
Type B PS SPA Imaging Beads

[125I] (Nle4-D-phe7) α-Melanocyte IM316
Stimulating Hormone ([125I]α-MSH), direct labeled


Other materials required
Human recombinant melanocortin (Euroscreen, ES-194-M)
MC5 receptor membrane preparation*

NDP-α-MSH (Sigma, M-8764)

α-Melanocyte Stimulating (Sigma, M-4135)
Hormone (α-MSH)

β-Melanocyte Stimulating (Sigma, M-6513)
Hormone (β-MSH)

384-well white flat bottom polystyrene (Corning, 3705)
not treated microplates

Assay buffer: 25 mM HEPES, pH 7.4
5 mM MgCl2
1 mM CaCl2
1 mM 1,10 phenathroline monohydrate
0.2% (w/v) protease-free BSA

GraphPad Prism™ software (GraphPad Software)

* Use of the receptor in this application note is not permitted in North America and Australia. For further information on the use of this receptor in restricted territories, please contact Euroscreen’s Business Development and Licensing Manager at vlannoy@euroscreen.be


Protocol
Human recombinant melanocortin MC5 receptor membrane preparation produced in CHO-K1 cells was used in conjunction with [125I] NDP-α-MSH (2000 Ci/mmol) and WGA PEI Type B PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 1-µM NDP-α-MSH. The standard assay format was as follows:

1. Reagents were added in the following order: assay buffer, unlabeled ligand (NSB wells), labeled ligand, and premixed bead and membrane*. Total assay volume was 40 µl.

2. Wells contained 10 µl (~ 44 000 dpm) of [125I] NDP-αMSH (0.25 nM/well), 0.125 mg of SPA Imaging Bead and 0.3125 µg of receptor preparation added tog ether in a 20-µl volume, and 10 µl of assay buffer in the absence of competing ligand. For competition assays, 10 µl of competing ligand prepared in assay buffer was added with [125I] NDP-α-MSH (10 µl, as above), premixed bead and receptor (20 µl), also giving a total assay volume of 40 µl.

3. NSB wells contained 10 µl of [125I] NDP-α-MSH (0.25-nM/well), 0.125 mg of SPA Imaging Bead and 0.3125 µg of receptor preparation added together in a 20-µl volume, and 10 µl of 4-µM unlabeled NDP-α-MSH (final concentration 1 µM).

4. For DMSO tolerance studies, DMSO was diluted in assay buffer to give final concentrations per well as shown in the results.

5. Plates were sealed and incubated overnight at room temperature (20–25 ºC).

6. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 5 min with quasi-coincident averaging and 3 ×3 binning.

7. For background estimation, bead-only wells (0.125 mg of bead/well, 10 µl), plus assay buffer (30 µl) were included in all experiments. Typically, backgrounds exhibited from bead-only wells were less than 10 integrated optical density (IOD) units and were routinely subtracted from total and NSB values during data analyses.

* Bead and diluted membrane were premixed at room temperature prior to assay addition.


Results
Kd determination
Saturation binding was carried out with dilutions of [125I] NDP-α-MSH to give a range of concentrations from 1.53 pM to 8.62 nM in the assay wells. Figure 1 shows the saturation curve which was fitted using non-linear regression with the data analysis package GraphPad Prism v4.0. A Kd value of 0.518 nM (95% conf idence intervals 0.4557 to 0.5803 nM) was estimated directly from the curve.

DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 1 to 10% DMSO (v/v) in the assay wells. The results in Figure 2 show that the assay is DMSO tolerant to 2% (v/v). Above 2% DMSO, an elevation in NSB is observed.

IC50 determination
Competition binding of 0.25-nM (~ 44 000 dpm) [125I] NDP-α-MSH with unlabeled NDP-α-MSH, and α-MSH were assessed and the IC50 values calculated as shown in Figure 3. For the competition assays, the unlabeled ligands NDP-α-MSH and α-MSH were prepared in assay buffer. The IC50 value for NDP-α-MSH was 0.1881 nM (95% confidence interval range 0.1525 to 0.2319 nM), Ki for NDP-α-MSH 0.1262 nM (95% confidence interval range 0.1024 to 0.1556 nM). The IC50 value for α-MSH was 26.66 nM (95% confidence interval range 20.76 to 34.24 nM), Ki for α-MSH was 17.89 nM (95% confidence interval range 13.93 to 22.98 nM).

Time course
A time course experiment was carried out using reagent concentrations as described in the protocol. Measurements were made over an assay incubation time of 20 h. The assay reached equilibrium after 5-h incubation at room temperature and the signal was stable for at least another 5 h (Fig 4).

Z’ analysis
A Z’ analysis was carried out using 48 replicate values for total and NSB wells. Z’ was 0.83 (Fig 5), which confirmed the robustness of the assay (2).


Conclusion
The melanocortin MC5 receptor binding a ssay has been successfully miniaturized to a 384-well format on LEADseeker Multimodality Imaging System and is suitable for high-throughput screening. The assay is tolerant up to 2% DMSO (v/v); is robust, exhibiting a Z’ value of 0.83, and has a stable signal of at least 10 h.


References
1. The Melanocortin System. Am. J. Physiol. Endocrinol. Metab. 284, E468–E474 (2003).

2. Zhang, J. et al, J. Biomol. Screening 4, 67–73 (1999).



back to top
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
3. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
4. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
5. The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
7. The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR
8. The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies
9. Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
10. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
11. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):